Disheartening News for AtheroGenics

Shares of the drug company plunged Monday after unfavorable results for its primary compound in a clinical trial

AtheroGenics (AGIX) had staked its business on a new drug called AGI-1067, which the Atlanta company hoped could combat a deadly accomplice of coronary disease -- clogged arteries. News hit March 19 that an advanced study of the drug has failed -- but researchers also discovered a few glimmers of encouraging information.

To continue reading this article you must be a Bloomberg Professional Service Subscriber.